21st week of 2010 patent applcation highlights part 35 |
Patent application number | Title | Published |
20100129329 | METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION - The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The first population comprises stem cells derived from umbilical cord. The second population comprises ALDHbr cells. These ALDHbr cells can be administered to a patient immediately after isolation or can be primed in culture using a combination of cytokines for about 2 to about 7 days prior to transplantation. The methods of the invention are useful in accelerating time to neutrophil and/or platelet engraftment and immune reconstitution following myeloablative therapy. | 2010-05-27 |
20100129330 | ADIPOCYTIC DIFFERENTIATED ADIPOSE DERIVED ADULT STEM CELLS AND USES THEREOF - The present invention is differentiated adipose tissue-derived stromal cells that exhibit the improved properties of increased extracellular matrix proteins and/or a lower amount of lipid than a mature isolated adipocyte. Methods for the expansion and differentiation of these cells are also provided. The cells of the invention are used for the treatment, repair, correction and/or regeneration of soft tissue cosmetic defects. | 2010-05-27 |
20100129331 | DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES - The present invention relates to the use of a series of disaccharides, as well as of compositions containing them, for the preparation of a medicament for the treatment or prevention of a tendon, ligament or bone disease, disorder or injury. The present invention also relates to the new compositions comprising a disaccharide in combination with inulin polysulphate, a glycosamino-glycan, a growth factor or cells. The glycosaminoglycan is preferably chondroitin sulphate or hyaluronic acid and the growth fact is IFG-1. | 2010-05-27 |
20100129332 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS - A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound. | 2010-05-27 |
20100129333 | ANTI-FATTY LIVER AGENT - Disclosed is an anti-fatty liver agent comprising a cell and/or a culture obtained by culturing a lactic acid bacterium belonging to | 2010-05-27 |
20100129334 | Use of Lactobacillus casei for Increasing the Protection Provided by the Influenza Vaccine - The invention relates to the use of | 2010-05-27 |
20100129335 | REDUCTION OF RISK DIARRHOEA - The use of a probiotic | 2010-05-27 |
20100129336 | Stabilized bacterial formulation - Selected strains of | 2010-05-27 |
20100129337 | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter - Strains of | 2010-05-27 |
20100129338 | SNAIL BAIT - The present invention relates to the use of a combination of potato preparation and yeast for improving the attractiveness of molluscicidal compositions for slugs and snails. It also relates to corresponding compositions, to processes for the preparation of these compositions, and to their use for controlling terrestrial slugs and snails. | 2010-05-27 |
20100129339 | NKT CELL-STIMULATING AGENT FOR ADMINISTRATION THROUGH UPPER RESPIRATORY TRACT MUCOUS MEMBRANE - The present invention provides an NKT cell stimulating agent containing antigen-presenting cells pulsed with an NKT cell ligand, to be administered submucosally in the upper airway. By submucosal administration in the upper airway, it is possible to stimulate NKT cells and stimulate immune reactions extremely efficiently with a small number of NKT cell ligand-pulsed antigen-presenting cells. By submucosal administration in the upper airway, NKT cells can be induced selectively in cervical lymph nodes. | 2010-05-27 |
20100129340 | METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS - Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25− T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed. | 2010-05-27 |
20100129341 | FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYROID HORMONE - Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented. | 2010-05-27 |
20100129342 | Human Growth and Differentiation Factor GDF-5 - This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. Said compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as for example growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The invention can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders. | 2010-05-27 |
20100129343 | Use Of A Compound For Enhancing The Expression Of Membrane Proteins On The Cell Surface - The present invention is directed to the use of a compound stimulating deubiquitinating activity in a cell for the manufacture of a medicament for enhancing the expression of integral membrane proteins on the cell surface. Especially, the invention is directed to the use of such compound for the manufacture of a medicament for the treatment of a disease of condition selected from the group consisting of cystic fibrosis, diabetes insipidus, hypercholesterinaemia and long QT-syndrome-2. | 2010-05-27 |
20100129344 | MEDICAL USES AND THERAPIES BASED UPON THE ACTION OF AZUROCIDIN ON IGFBP-1 - The present invention concerns the use of azurocidin in the manufacture of a medicament for treating conditions associated with hepatic insulin resistance. Further provided is the use of a modulator of the interaction between azurocidin and IGFBP-1 in the manufacture of a medicament for use in the treatment of a condition which is associated with IGFBP-1 and/or IGF level and/or activity. Methods of treatment, an octopeptide modulator of amino acid sequence WDAISTYD, pharmaceutical compositions comprising the modulators of azurocidin and IGFBP-1 and uses thereof in the treatment of conditions associated with IGFBP-1 and/or IGF level and/or activity are also provided. | 2010-05-27 |
20100129345 | SCREENING METHOD FOR PROKINETIC AGENT - The present invention provides a screening tool and screening method for obtaining a substance useful as a prophylactic and/or therapeutic drug for diseases associated 5 with 5-HT production/secretion abnormalities, including digestive organ diseases, and a prophylactic and/or therapeutic drug for diseases associated with 5-HT production/secretion abnormalities, including digestive organ diseases. Examples of digestive organ diseases in the present invention include constipation type irritable bowel syndrome, functional dyspepsia, constipation, diarrhea type irritable bowel syndrome, diarrhea and vomiting. | 2010-05-27 |
20100129346 | Anti-C5aR Antibodies With Improved Properties - The present invention relates to improved antibodies which bind to C5aR and which are useful in diagnosis and therapeutic methods. | 2010-05-27 |
20100129347 | HERPES VIRUS INFECTION INHIBITOR, METHOD FOR INHIBITING INFECTION WITH HERPES VIRUS, AND USE THEREOF - Disclosed are: an inhibitor of herpesvirus infection; a method for the inhibition of herpesvirus infection; and a typical utilization method thereof. The inhibitor of herpesvirus infection comprises an active ingredient which can bind to glycoprotein B or a receptor for glycoprotein B and can inhibit the interaction between glycoprotein B and a receptor for glycoprotein B. | 2010-05-27 |
20100129348 | METHOD FOR DECREASING DEPRESSION BY INHIBITING THE ACTIVITY OF ALPHA 1B SUBUNIT OF N-TYPE CALCIUM CHANNEL - The present invention relates to the method for decreasing depression, more particularly to the method for decreasing depression by inhibiting the activity of alpha 1B subunit of N-type calcium channel. According to the present invention, inhibiting material of alpha 1B subunit of N-type calcium channel can effectively be used for the depression remedy. Also, anti-depression reagent can be screened using alpha 1B subunit of N-type calcium channel. | 2010-05-27 |
20100129349 | Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus - Methods of inhibiting | 2010-05-27 |
20100129350 | Triazine Derivatives, Compositions Containing Such Derivatives, and Methods of Treatment of Cancer and Autoimmune Diseases Using Such Derivatives - We describe compounds of the following general formula (I): wherein X is fluorine or chlorine; Y is oxygen, sulfur, or an amino group; R is an amino, hydroxyl, sulfonamide, or carboxamide group or an N-monomethyl or N-dimethyl analog thereof; m is an integer from 2 to 6, and n is an integer from 0 to 2. The compounds may be used for treating certain cancers and autoimmune diseases. | 2010-05-27 |
20100129351 | Compositions and Methods for Altering Pancreas or Liver Function - Methods for altering pancreatic and liver cell function are provided, wherein the compositions and methods are based on use of netrin-4 or on altering the activity of netrin-4. | 2010-05-27 |
20100129352 | NOVEL PHARMACEUTICAL COMPOSITION - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 2010-05-27 |
20100129353 | COMBINATION AND TREATMENT FOR MULTIPLE SCLEROSIS - This invention is directed towards treatments for multiple sclerosis comprising administering to a patient in need thereof a first agent, such as 2-chloro-2′-deoxyadenosine (2-CdA), that reduces the number of lymphocytes in combination with a second agent, such as an anti-alpha-4 integrin antibody, that blocks the adhesion of monocytes and leukocytes to endothelial cells. The use of 2-CdA combined with an anti-alpha-4 integrin antibody may be more effective than either treatment alone for MS. Furthermore, the combination treatment may allow for a lowering or altering the dose of one or more of the agents in order to limit any adverse effects associated with the individual agents, but maintaining the same therapeutic efficacy. | 2010-05-27 |
20100129354 | INTRANASAL DELIVERY OF POLYPEPTIDES AND PROTEINS - The present invention relates to the intranasal delivery of therapeutic polypeptides and proteins comprising a Nanobody®, a domain antibody, a single domain antibody or a “dAb”. The present invention provides compositions comprising a therapeutically effective amount of such polypeptide or protein and further comprising a pharmaceutically acceptable nasal carrier. The invention also relates to methods for the treatment of a subject comprising the delivery of said polypeptides and proteins to said subject by the nasal route. | 2010-05-27 |
20100129355 | THERAPEUTIC AGENTS FOR OCULAR INFLAMMATORY DISEASE COMPRISING INTERLEUKIN 6 RECEPTOR INHIBITOR AS ACTIVE INGREDIENT - The present invention relates to therapeutic and/or prophylactic agents for ocular inflammatory disease, which comprise an interleukin 6 (IL-6) receptor inhibitor as an active ingredient. | 2010-05-27 |
20100129356 | COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT - The present invention provides methods of using a DLL4 modulator to modulate vascular development. Furthermore, methods of treatment using DLL4 modulators, such as DLL4 antagonists, are provided. | 2010-05-27 |
20100129357 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. | 2010-05-27 |
20100129358 | METHOD OF DETECTING OCULAR DISEASES AND PATHOLOGIC CONDITIONS AND TREATMENT OF SAME - Ocular diseases affecting the macula or the vasculature of the eye affect a wide variety of individuals. In particular, Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the developed world and has a significant genetic predisposition. Methods of analyzing one or more mutations in the HtrA1 gene in order to identify individuals with a presusceptability to development of an ocular disease and a pathologic condition of the eye and diagnose those currently suffering from an ocular disease or a pathologic condition of the eye are provided. The methods of the present invention may further include analysis of the CFH gene in order to identify individuals with a presusceptability to development of an ocular disease and a pathologic condition of the eye and diagnose those currently suffering from an ocular disease or a pathologic condition of the eye. Compositions and methods for treating ocular disease and pathologic conditions of the eye are also provided. | 2010-05-27 |
20100129359 | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers - A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispinal space of said human without direct intrathecal injection and positioning said human in a Trendelenburg position. | 2010-05-27 |
20100129360 | ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 AND USES THEREFOR - This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders. | 2010-05-27 |
20100129361 | IMMUNOSUPPRESSION WITH ANTIBODY AGAINST ITM2A - The invention relates to methods of T cell immune system modulation and the treatment of immune system related diseases and disorders. In particularly, embodiments of the invention provides immunotherapeutics in the form of antibodies, bioengmeered antibodies and recombinant proteins for the treatment of autoimmune diseases and disorders, organ transplantation rejection, graft-versus-host tissue diseases, and T-cell based lymphoma and leukemia. | 2010-05-27 |
20100129362 | TREATMENT OF PSORIATIC ARTHRITIS WITH ANTI-CD70 ANTIBODY - Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment of psoriatic arthritis comprising administering the CD70 binding agents to a subject. | 2010-05-27 |
20100129363 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF CANCERS - Methods of treating, preventing and/or managing hematological cancers are disclosed. Specific methods encompass the administration of a PDE4 inhibitor alone or in combination with a second active agent. The invention further relates to methods of treating leukemias and lymphomas which comprise the administration of a PDE4 inhibitor. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2010-05-27 |
20100129364 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder. | 2010-05-27 |
20100129365 | TREATMENT OF INFLAMMATION USING BST2 INHIBITOR - The application discloses a method of preventing immune cells from binding to other cells, which includes contacting the immune cells and the other cells with a composition comprising Bst2 antagonist. | 2010-05-27 |
20100129366 | THIAZOLE INHIBITORS OF CYCLOOXYGENASE - The present invention relates to new thiazole inhibitors of cyclooxygenase, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-27 |
20100129367 | HUMAN BETA-GLUCURONIDASE MUTANTS WITH ELEVATED ENZYMATIC ACTIVITY UNDER PHYSIOLOGICAL CONDITIONS AND METHOD FOR IDENTIFYING SUCH - A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system. | 2010-05-27 |
20100129368 | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof - The present invention relates to amino acid sequences that binding to serum proteins such as serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides, is essentially independent in the pH range 5 to 8. | 2010-05-27 |
20100129369 | c-Met Antibodies - Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met. | 2010-05-27 |
20100129370 | Trefoil Factors and Methods of Treating Proliferation Disorders Using Same - The present invention relates to methods of regulation of cellular proliferation and/or survival, particularly methods for the treatment of proliferative disorders. The invention also relates to agents and compositions of use in such methods. | 2010-05-27 |
20100129371 | Method for genetic immunization by electrotransfer against a toxin and antiserum obtainable by said method - The invention concerns a method for obtaining an antiserum directed against a proteinic toxin by administering to an animal a solution comprising a genetic construct encoding a toxin immunogenic fragment, then applying an electric field in the administering zone, and isolating the serum. The invention also concerns the antiserum obtainable by the method as well as the use of the solution for making a medicine for preventing or treating a toxic effect related to absorption by a mammal of a toxin. The invention is characterized in that said medicine is formulated to be administered by electrotransfer. | 2010-05-27 |
20100129372 | INHIBITION OF PACAP SIGNALLING FOR THE PREVENTION AND TREATMENT OF THROMBOCYTOPENIA - The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia). | 2010-05-27 |
20100129373 | VEGF-SPECIFIC HUMAN ANTIBODY - The present invention relates to a vascular endothelial growth factor (VEGF)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF-specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation. | 2010-05-27 |
20100129374 | Mammalian Cell Membrane Proteins; Related Reagents - The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use. | 2010-05-27 |
20100129375 | METHODS FOR INHIBITING OCULAR ANGIOGENESIS - The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders. | 2010-05-27 |
20100129376 | Osteopontin Specific Antibodies and Methods of Use Thereof - Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders. | 2010-05-27 |
20100129377 | MILK DERIVED ANTIGEN-SPECIFIC ANTIBODIES, METHODS OF PREPARATION AND USES THEREOF - The invention relates to means and methods for obtaining an antigen specific antibody from milk from non-human mammals that have not been immunized with said antigen prior to collecting said milk. Non-human mammal derived antigen specific antibody was found to cross the mucosal side of the intestinal tract of an individual. The invention provides novel means and methods for the treatment of disease through antigen specific non-human mammal antibodies. Further provided are preparations for oral administration comprising said antigen specific antibody of a ruminant. | 2010-05-27 |
20100129378 | TREATMENT AND DIAGNOSIS OF ABNORMAL BONE DENSITY WITH AN INHIBITOR OF THE GLYPICAN-SCLEROSTIN INTERACTION - Compositions and methods of treatment for abnormal bone density are disclosed based upon the finding that sclerostin must be bound to glypican in order to inhibit bone deposition. Methods for identifying agents that inhibit the glypican-sclerostin interaction are disclosed for treatment of bone deposition disorders. Diagnostic methods are also disclosed. | 2010-05-27 |
20100129379 | STABILIZED ANTIBODY FORMULATIONS AND USES THEREOF - The present invention provides methods of optimizing certain stable liquid formulations of antibodies that immunospecifically bind to antigens of interest. Such formulations are suitable for parenteral administration to a subject, and exhibit increased stability, low to undetectable levels of aggregation, low to undetectable levels of antibody fragmentation/degradation, and very little to no loss of the biological activities of the antibodies, even during long periods of storage. The methods of the invention provide formulations that offer multiple advantages over formulations produced by non-optimized methods, including less stringent or more readily available transportation and storage conditions, less frequent dosing, and/or smaller dosage amounts in the therapeutic, prophylactic and diagnostic uses of such formulations. The invention further provides methods of identifying antibodies exhibiting certain phase behaviors such that the antibodies can be formulated by the methods of the invention. Also provided are prophylactic, therapeutic, and diagnostic uses of such antibody formulations. | 2010-05-27 |
20100129380 | Antibodies Against IL-25 - The invention provides the antibody 2C3 and target binding members based on 2C3 which binds interleukin-25. These are useful in therapy, e.g. the treatment of asthma. | 2010-05-27 |
20100129381 | ANTI-FGF19 ANTIBODIES AND METHODS USING SAME - The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4. | 2010-05-27 |
20100129382 | COMBINATION THERAPY FOR THE TREATMENT OF TUMORS - The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin. | 2010-05-27 |
20100129383 | BIFUNCTIONAL FUSION MOLECULES FOR THE DELIVERY OF ANTIGENS TO PROFESSIONAL ANTIGEN-PRESENTING CELLS - The invention provides a bifunctional fusion molecule comprising: a first functional domain comprising a first immunoglobulin variable region, a second immunoglobulin variable region and a linker for connecting the first and second variable regions; a second functional domain comprising a moiety for binding to an antigenic agent; wherein the first and second functional domains are linked; and wherein the first functional domain specifically binds to a surface molecule of a professional antigen-presenting cell, and uses thereof. | 2010-05-27 |
20100129384 | TACI-IMMUNOGLOBULIN FUSION PROTEINS - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors. | 2010-05-27 |
20100129385 | IMMUNOGENIC MOLECULES - The present invention relates generally to the field of immunology and more particularly to molecules capable of stimulating a cellular immune response. More particularly, the present invention provides self-adjuvanting immunogenic molecules capable of stimulating an immune response to epitopes of a polypeptide irrespective of a subjects HLA type. The present invention further contemplates methods for the production and use of the self-adjuvanting immunogenic molecules and compositions comprising same useful in the vaccination of subjects against specific polypeptides. | 2010-05-27 |
20100129386 | Composotions And Methods For The Identification And Treatment Of Immune-Mediated Inflammatory Diseases - Compositions and methods for the therapy and diagnosis of immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention or treatment of immune-mediated inflammatory disease. | 2010-05-27 |
20100129387 | PHARMACEUTICAL COMPOSITION CONTAINING THE NMB0606 PROTEIN - The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0606 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0606 protein was identified as a | 2010-05-27 |
20100129388 | PROTECTIVE PROTEINS OF S. AGALACTIAE, COMBINATIONS THEREOF AND METHODS OF USING THE SAME - The invention relates to a composition comprising at least two protective proteins against | 2010-05-27 |
20100129389 | METHODS OF MODULATING HVEM, BTLA AND CD160 CIS COMPLEX RESPONSE OR SIGNALING ACTIVITY WITH SOLUBLE LIGHT POLYPEPTIDE SEQUENCES - The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., LIGHT polypeptide sequence) that bind to the HVEM cis complexes. | 2010-05-27 |
20100129390 | DKK1 AS A UNIVERSAL TUMOR VACCINE FOR IMMUNOTHERAPY OF CANCERS - DKK1 compositions comprising a DKK1 protein, DKK1 peptide, DKK1 DNA, DKK1-specific CTLs and Th1 cells and associated methods for treating cancer and cancer-mediated disorders in a human or animal subject in need of such treatment by administering a DKK1 composition to prevent or treat cancer are disclosed herein. The DKK1 compositions can be used alone, or in combination with other treatments, for the treatment of various cancers including ovarian, breast, colonic, brain, lung, prostate, pancreatic, lymphoma, esophageal carcinomas and melanoma. | 2010-05-27 |
20100129391 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF - The present invention relates to compositions and fusion proteins containing at least two | 2010-05-27 |
20100129392 | Targeting of Antigen Presenting Cells with Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 2010-05-27 |
20100129393 | NOVEL USE OF L. UNDULATA EXTRACT AS THERAPEUTICS FOR ALLERGIC DISEASES - The present invention relates to a method of preventing or treating allergic diseases such as allergic rhinitis, atopic dermatitis, anaphylaxis, and asthma, which comprises administering an extract of | 2010-05-27 |
20100129394 | Robust Expression of a Bioactive Mammalian Protein in Chlamydomonas Chloroplast - Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of recombinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble protein where the functional activity of the peptide is intact. As the host algae is edible, production of biologics in this organism for oral delivery of proteins/peptides, especially gut active proteins, without purification is disclosed. | 2010-05-27 |
20100129395 | Hapten-carrier conjugates and uses thereof - The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction. | 2010-05-27 |
20100129396 | V. CHOLERAE HYPEREXPRESSING RECOMBINANT CHOLERA TOXIN B SUBUNIT SHOWING DUAL IMMUNOGENICITY - Oral immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing | 2010-05-27 |
20100129397 | EFFECTIVE METHOD OF TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and | 2010-05-27 |
20100129398 | Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome - Methods of reducing the severity of porcine reproductive and respiratory syndrome virus (PRRSV) infections, as well as, methods of preventing such infections are provided. The methods provide for the age-based innoculation of swine with PRRS antigen, preferably Ingelvac® ATP. | 2010-05-27 |
20100129399 | LINEAR EXPRESSION CONSTRUCTS FOR PRODUCTION OF INFLUENZA VIRUS PARTICLES - The present invention provides a linear expression construct free of any conventional amplification and/or selection sequences comprising an RNA polymerase I (polI) promoter and a polI termination signal, inserted between a RNA polymerase II (polII) promoter and a polyadenylation signal useful for the expression of segments of viral RNA, preferably influenza viruses. The inventive construct is useful for efficient and fast production of viral particles, especially for producing vaccine formulations for the treatment of epidemic and/or pandemic diseases. | 2010-05-27 |
20100129400 | ATTENUATED VIRUSES, VACCINES AND METHODS OF USE THEREOF - The invention encompasses compositions and methods relating to viral polymerases having one or more substitutions of different amino acids at conserved regions of the polymerase yields enzymes with varying rates and fidelity of replication. A universally applicable, polymerase-mechanism-based strategy for production of attenuated viruses and anti-viral vaccines is disclosed. Attenuated viruses serve as vaccines and were shown to provide protection against poliovirus challenge in vivo. | 2010-05-27 |
20100129401 | Functional Influenza Virus Like Particles (VLPs) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 2010-05-27 |
20100129402 | DOUBLE-EFFECTIVE VACCINE VECTOR AGAINST FOOT-AND-MOUTH DISEASE VIRUS (FMDV), METHODS OF PREPARING AND USING THE SAME - A double-effective vaccine vector against foot-and-mouth disease virus having a bicistronic expression vector sequence, the bicistronic expression vector sequence is an antisense gene sequence capable of conjugating with 5′ UTR of RNA of the foot-and-mouth disease virus genome and an intact sequence of VP1 structural protein gene of the foot-and-mouth disease virus. Animal experiments show that the vaccine vector provides double effects in terms of gene therapy and gene immunization for the prevention and treatment of foot-and-mouth disease in animals. Also provided are construction methods and methods of use of the vaccine vector. | 2010-05-27 |
20100129403 | RECOMBINANT VIRAL VACCINE - The present invention concerns new recombinant viral vaccines. In particular the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors. | 2010-05-27 |
20100129404 | IMMEDIATE PROTECTION AGAINST PATHOGENS VIA MVA - The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen. | 2010-05-27 |
20100129405 | ISOLATION, CLONING AND CHARACTERIZATION OF NEW ADENO-ASSOCIATED VIRUS (AAV) SEROTYPES - The present invention provides new adeno-associated virus (AAV) viruses and vectors, and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV vectors and particles. | 2010-05-27 |
20100129406 | HOLIN-ENHANCED VACCINES AND REAGENTS, AND METHODS OF USE THEREOF - The invention provides | 2010-05-27 |
20100129407 | Tuberculosis Vaccine - The present invention relates to an isolated microorganism belonging to the genus | 2010-05-27 |
20100129408 | KLEBSIELLA PNEUMONIAE ATTENUATED VIRULENCE MUTANT AND METHOD OF PRODUCTION - The present invention relates to a | 2010-05-27 |
20100129409 | Novel Prostate Kallikrein Allergen - Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs. | 2010-05-27 |
20100129410 | Methods and Immunogenic Cell Preparations for Treating Antigen-Associated Diseases - A method of inhibiting growth of, reducing or eliminating a cell population of a subject in need thereof is disclosed. The method comprises (a) thermally, mechanically and/or chemically damaging antigen-bearing cells which comprise at least one antigen characterizing cells of the cell population, with the proviso that the chemically damaging of the antigen-bearing cells is not predominantly effected using one or more antineoplastic agents, thereby generating immunogenic cells; and (b) introducing in the subject a cell aggregate which comprises the immunogenic cells and added antigen-presenting cells, thereby inducing an immune response for inhibiting growth of, reducing or eliminating the cell population of the subject. | 2010-05-27 |
20100129411 | FIVE-LAYERED PIGMENTS - The present invention relates to five-layered pigments based on multicoated platelet-shaped substrates which comprise a layer sequence comprising
| 2010-05-27 |
20100129412 | BRIGHT PIGMENT AND COSMETIC COMPOSITION USING THE SAME - The bright pigment of the present invention contains a scaly substrate | 2010-05-27 |
20100129413 | METHOD OF TREATING AND PREVENTING VIRAL INFECTIONS - A method for treatment of a viral infection in a mammal comprising a step of administering a composition containing an amount of selenium (Se) effective to raise the serum level of the mammal to at least 15 μg/L above baseline. | 2010-05-27 |
20100129414 | Bioactive Agent Delivery Using Liposomes in Conjunction With Stent Deployment - Described herein are methods for treating aneurysms, vascular occlusions, and vascular lesions. The methods comprise the use of an implantable medical device which includes a bioactive agent substrate associated with its surface. Liposomes are used to encapsulate the bioactive agent and are delivered either systemically or locally to the bloodstream. A means for liberating the bioactive agents from the liposomes is used once an appropriate location is chosen and the liposomes have distributed themselves through the vasculature. Once liberated, the bioactive agent can be sequestered by the bioactive agent substrate associated with the implantable medical device, and slowly released to impart a therapeutic effect on the surrounding tissues. | 2010-05-27 |
20100129415 | BONE REGENERATION DEVICE - This invention is directed to a bone regeneration device including fascia and demineralized bone matrix mixed at a temperature not exceeding about 40° C. and lyophilized into the bone regeneration device, methods of preparing such a bone regeneration device and methods of treating bone defects using such a bone regeneration device. | 2010-05-27 |
20100129416 | BIOACTIVE LOAD-BEARING COMPOSITES - Methods of preparing bioactive composites are described. Also described are methods of molding such composites. Shaped bodies comprising bioactive composites are further described. | 2010-05-27 |
20100129417 | Dihydroxybenzoate Polymers and Uses Thereof - The present invention is directed to polyphenolic polymers formed from dihydroxybenzoic acid (DHB) derivatives or from resorcinol derivatives, monomers which form such polymers, blends of the polymers with drugs and/or additional polymers, as well as medical devices formed from, coated with, impregnated by or coverings made with any of the foregoing polymers (with or without drugs) or blends (with or without drugs). | 2010-05-27 |
20100129418 | METHOD OF INDUCING NEGATIVE CHEMOTAXIS USING AN ELLAGITANNIN OR GALLOTANNIN - The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of an ellagitannin and a gallotannin. In one embodiment, the compound is ellagic acid or a pharmaceutically acceptable salt thereof. | 2010-05-27 |
20100129419 | METHODS AND COMPOSITIONS FOR BLOCKING PLATELET AND CELL ADHESION, CELL MIGRATION AND INFLAMMATION - The present invention provides compositions of saratin and methods of use thereof. One aspect of the invention is a method of prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Another aspect of the invention is a method for treatment of flexor tendon injuries. | 2010-05-27 |
20100129420 | METHODS AND DEVICES TO ACCELERATE WOUND HEALING IN THORACIC ANASTOMOSIS APPLICATIONS - A long term oxygen therapy system having an oxygen supply directly linked with a patient's lung or lungs may be utilized to more efficiently treat hypoxia caused by chronic obstructive pulmonary disease such as emphysema and chronic bronchitis. The system includes an oxygen source, one or more valves and fluid carrying conduits. The fluid carrying conduits link the oxygen source to diseased sites within the patient's lungs. A collateral ventilation bypass trap system directly linked with a patient's lung or lungs may be utilized to increase the expiratory flow from the diseased lung or lungs, thereby treating another aspect of chronic obstructive pulmonary disease. The system includes a trap, a filter/one-way valve and an air carrying conduit. In various embodiments, the system may be intrathoracic, extrathoracic or a combination thereof A pulmonary decompression device may also be utilized to remove trapped air in the lung or lungs, thereby reducing the volume of diseased lung tissue. A lung reduction device may passively decompress the lung or lungs. In order for the system to be effective, an airtight seal between the parietal and visceral pleurae is required. Chemical pleurodesis is utilized for creating the seal and various devices and/or drugs, agents and/or compounds may be utilized to accelerate wound healing in thoracic anastomosis applications. | 2010-05-27 |
20100129421 | COMPOSITION FOR PROMOTING BONE REGENERATION AND RESTORATION - A bone grafting material composite is provided. The bone grafting material composite includes a demineralized bone matrix (DBM) and a carboxymethyl cellulose (CMC)/glycerol gel carrier. Due to the CMC/glycerol gel carrier, the implantation ability thereof is better than that of the DBM. Therefore, the bone grafting material composite can be easily used, so that a curative effect can be greatly improved. In addition, since the CMC/glycerol gel is used as a carrier, the composite with a mobility maintained is washed out by water after surgery, so that the composite can be fixed on a damaged portion of a bone. | 2010-05-27 |
20100129422 | POROUS BIODEGRADABLE POLYMER SCAFFOLDS FOR IN SITU TISSUE REGENERATION AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to an intelligent porous biodegradable polymer scaffold for in situ tissue regeneration in which two kinds of physiologically active substances having high differentiation potential and biocompatibility are introduced into the polymer scaffold and conjugated to the surface thereof, respectively, and a method for the preparation thereof. Since the intelligent porous biodegradable polymer scaffold exhibits improved biocompatibility and differentiation potential due to the introduction of physiologically active substances capable of efficiently inducing cell proliferation and differentiation into both the surface and the inside thereof, it can directly induce in situ tissue regeneration of the musculoskeletal system from stem cells in a living tissue after transplanting the polymer scaffold and stem cells into a human body without additional in vitro cultivation. Therefore, the intelligent porous biodegradable polymer scaffold according to the present invention can be effectively used in the regeneration of various kinds of tissues and organs including the musculoskeletal system. | 2010-05-27 |
20100129423 | DEVICE MADE AT LEAST PARTIALLY OF N-ACETYLCHITOSAN WITH CONTROLLED BIODISSOLUTION - A method of biodissolving in an aqueous medium at least a part of a device, the part of the device being made of N-acetylchitosan with a degree of acetylation of more than 3% and less than 25%. In the method, the biodissolution of the part of the device is controlled by adjusting the pH of the aqueous medium in contact with the N-acetylchitosan part of the device to a value of equal or less than 6.0. | 2010-05-27 |
20100129424 | Contact drug delivery system - A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having coamplexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed preferably mimics receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. The system in accordance with an embodiment of the intention is a contact lens for delivering a drug through contact with an eye. | 2010-05-27 |
20100129425 | VAGINAL DELIVERY SYSTEM FOR MIRTAZAPINE - This invention relates to an extended release formulation comprising solid mirtazapine, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing mirtazapine. The polymer is preferably made of ethylene-vinyl acetate copolymer. | 2010-05-27 |
20100129426 | PROTECTIVE AGENT AGAINST DAMAGE OF BIOLOGICAL TISSUE CAUSED BY NEAR-INFRARED RAY AND PRODUCT COMPRISING THE SAME - The present invention is to provide a protective agent against damage of biological tissue caused by near-infrared rays which is capable of blocking the near-infrared rays from reaching not only skin but also deeper tissue than the skin tissue, preventing damage of such tissue caused by the near-infrared rays and preventing pathogenesis and development of various disease and acceleration of aging both of which are caused by the near-infrared rays, and a product using the protective agent. The protective agent against damage of biological tissue caused by near-infrared rays comprises a near-infrared ray penetration blocker that absorbs, reflects or scatters the near-infrared rays to prevent the damage of skin and deeper tissue than the skin in a living body caused by exposure with the near-infrared rays. | 2010-05-27 |
20100129427 | Hemostatic Wound Dressings - Hemostatic wound dressings for substantially arresting the flow of severe, life threatening bleeding from a wound by rapidly adhering to the wound site, absorbing and concentrating and thickening the blood at the dressing blood interface and accelerating the natural clot formation beneath the dressing and finally, forming a strong seal that will substantially prohibits further flow of blood out of the wound site. These hemostatic wound dressings are formed of unique combinations of hemostatic dressing aspects which achieve wound seal strengths that are significantly higher than the sum of seal strengths expected from the individual aspects alone. Some embodiments also achieve these synergistic seal strengths by combining one hemostatic dressing with a non-hemostatic device. | 2010-05-27 |
20100129428 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL - The instant invention is drawn to a hepatocyte targeted composition comprising interferon associated with a lipid construct comprising amphipathic lipid molecules and receptor binding molecule. The composition can comprise a mixture of free interferon and interferon associated with the complex. The composition can be modified to protect interferon and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading interferon into the composition and recycling various components of the composition and methods of treating individuals infected with the hepatitis C and other hepatitis viruses. | 2010-05-27 |